Published: February 2021
mRNA as a therapeutic / preventive agent has been demonstrated to be well tolerated in vivo, and can harness the cell’s translational machinery to invoke humoral and cell-mediated immune responses
Roots Analysis has announced the addition of “mRNA Therapeutics and Vaccines Market, 2020-2030” report to its list of offerings.
With over 150 candidates under development for various therapeutic areas, including (but not limited to) infectious diseases, genetic diseases, and oncological disorders, the future of this segment of the biopharmaceutical market seems promising. The recent approval of two mRNA vaccine candidates for the prevention of COVID-19 has provided a notable boost to the growth of this niche and emerging class of biologics. Experts believe that mRNA can be used to address the challenges associated with delivery of synthetically manufactured proteins
To order this 200+ page report, which features 70+ figures and 85+ tables, please visit this link
~ 150 mRNA therapeutics and vaccines are currently under development across different stages
The current pipeline includes 78 therapy candidates and 77 vaccines. The market is still in its infancy with 76% of the aforementioned candidates are in preclinical and discovery stages; over 20% of mRNA-based leads are being evaluated in clinical trials.
Over 70 of the investigational leads use Lipid Nanoparticle as a delivery vehicle
Other delivery vehicles that are being explored by developers include lipopolyplexes, lipoplexes, nanoparticles, and liposomes; certain mRNA molecules have been modified to be delivered without the need for a delivery vehicle.
Around 50% the developers of mRNA vaccines and therapeutics are based in North America
Post 2016, there has been a significant rise in the number of companies involved in this domain. It is also worth noting that, within North America, most of the developers are based in the US, which is presently considered a key R&D hub for advanced therapeutic products.
Over USD 9 billion has been invested by both private and public investors, since 2010
Companies involved in the development of mRNA-based pharmacological products have raised around USD 3 billion through venture capital financing, representing 32% of the total capital raised since 2010. The report provides details of 15 instances where grants were awarded to fund mRNA-based therapy / vaccine development efforts.
Partnership activity in this field has grown at a CAGR of ~35%, between 2013 and 2020
More than 80% of the reported deals were established after 2015, with the maximum activity being reported in 2020. One of the key drivers of partnership activity in this domain was the need for bulk manufacturing of mRNA vaccines for COVID-19. Other popular deal models include research agreements (26%) and manufacturing services agreement (11%).
Europe and North America are anticipated to capture over 70% of market share in 2021
The current market size is primarily driven by revenues from the sales of the mRNA-based vaccines for the prevention of COVID-19. By 2030, products designed for delivery via intramuscular route are expected to be responsible for the largest market share (75%) in terms of revenues from product sales, followed by those designed to be delivered via the intradermal (18%) and epicardial (7%) routes.
To request a sample copy / brochure of this report, please visit this link
The USD 10 billion (by 2021) financial opportunity within the mRNA Vaccines and Therapeutics market has been analysed across the following segments:
The research includes brief profiles of mRNA candidates, featuring information on drug name, route of administration, developer name, highest phase of development, target disease indication and therapeutic area, structure and mechanism of action, technology used, type of candidate, partnerships, overview of clinical trials, clinical trial results and other recent developments (if available).
For additional details, please visit https://www.rootsanalysis.com/reports/mrna-therapeutics-and-vaccines-market.html
or email email@example.com
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry